## SUPPLEMENTARY MATERIAL

Neogenkwanine I from the flower buds of *Daphne genkwa* with its stereostructure confirmation using quantum calculation profiles and antitumor evaluation

Xue-wen Hou<sup>a</sup>, Shuang Han<sup>a</sup>, Ying-ying Zhang<sup>a</sup>, Hai-bi Su<sup>a</sup>, Pin-yi Gao<sup>a,b</sup>, Ling-zhi Li<sup>\*a</sup> and Shao-jiang Song<sup>\*a</sup>

<sup>a</sup>School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China; <sup>b</sup>College of Pharmaceutical and Biotechnology Engineering, Institute of Functional Molecules, Shenyang University of Chemical Technology, 11 Street, Shenyang economic and Technological Development Zone, Shenyang 110142, China

## CONTACT

Shao-jiang Song, Ling-zhi Li

E-mail: songsj99@163.com, lilingzhijessie@163.com.

## ABSTRACT

Neogenkwanine I (1), a new daphnane-type diterpene with 4,7-ether group, along with four known ones (2–5), were isolated from *Daphne genkwa*. The structure including absolute configurations of 1 was established on the basis of NMR, <sup>13</sup>C-NMR and ECD calculations and CD exciton chirality analysis. <sup>13</sup>C-NMR and ECD calculations of daphnane-type diterpenes were reported here for the first time. All of the diterpenes were screened for their cytotoxic activities against MCF-7 and Hep3B cell lines. The cytotoxicity structure- activity relationship of compounds was illustrated with the absence of ortho- ester group of daphnane-type diterpenes.

**KEYWORDS** *Daphne genkwa*; daphnane-type diterpenes; <sup>13</sup>C-NMR and ECD calculations; cytotoxicity; structure-activity relationship

## **Table of Contents**

- Figure S1. <sup>1</sup>H-NMR spectrum (600 MHz, Chloroform-*d*) of compound 1
- Figure S2. <sup>13</sup>C-NMR spectrum (100 MHz, Chloroform-*d*) of compound 1
- Figure S3. HMBC spectrum (600 MHz, Chloroform-d) of compound 1
- Figure S4. HSQC spectrum (600 MHz, Chloroform-*d*) of compound 1
- Figure S5. NOESY spectrum (600 MHz, Chloroform-d) of compound 1
- Figure S6. CD spectrum of compound 1
- Figure S7. HRESIMS spectrum of compound 1
- Figure S8. Key HMBC correlations of 1.
- Figure S9. Key NOESY correlations of 1.

**Figure S10**. (a) Experimental and calculated <sup>13</sup>C chemical shifts of  $(2S^*, 3S^*, 4R^*, 5R^*, 6S^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1. Regression analysis of experimental versus calculated <sup>13</sup>C-NMR chemical shifts of  $(2S^*, 3S^*, 4R^*, 5R^*, 6S^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 at the TMS B3LYP/6-311 + G(2d,p) GIAO level. Linear fitting is shown as a line. (b) Comparison of calculated ECD spectra with the experimental spectrum of 1.

- Figure S11. Correlation between experimental and calculated <sup>13</sup>C chemical shifts of  $(2S^*, 3S^*, 4R^*, 5R^*, 6S^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 (a) and  $(2S^*, 3S^*, 4R^*, 5R^*, 6R^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 (b)
- Figure S12. Stereoviewsfor 2S,3S,4R,5R,6S,7R,8S,9R,10S,11R,13R,14R and 2R,3R, 44S,5S, 6R,7S,8R,9S,10R,11S,13S,14S of compound 1. Bold lines denote the electric transition dipole of the chromophores for compound 1.
- Table S1.
   <sup>1</sup>H and <sup>13</sup>C-NMR spectral data of compound 1
- Table S2.
   Cytotoxic activities of compounds 1-5 against the Hep3B and MCF-7 cell lines.
- **Table S3.** Conformations of  $(2S^*, 3S^*, 4R^*, 5R^*, 6S^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 were obtained after the optimization.
- **Table S4.** Conformations of  $(2S^*, 3S^*, 4R^*, 5R^*, 6R^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 were obtained after the optimization.
- **Table S5.** Deviations between the calculated and experimental  $^{13}$ C-NMR chemical<br/>shifts for stereoisomers ( $2S^*$ , $3S^*$ , $4R^*$ , $5R^*$ , $6S^*$ , $7R^*$ , $8S^*$ , $9R^*$ , $10S^*$ , $11R^*$ ,<br/> $13R^*$ , $14R^*$  and  $2S^*$ , $3S^*$ , $4R^*$ , $5R^*$ ,  $6R^*$ , $7R^*$ , $8S^*$ , $9R^*$ , $10S^*$ , $11R^*$ , $13R^*$ ,

14*R*\*) of **1**.




Figure S1. <sup>1</sup>H-NMR spectrum (600 MHz, Chloroform-*d*) of compound 1




Figure S2. <sup>13</sup>C-NMR spectrum (100 MHz, Chloroform-*d*) of compound 1




Figure S3. HMBC spectrum (600 MHz, Chloroform-d) of compound 1




Figure S4. HSQC spectrum (600 MHz, Chloroform-d) of compound 1





Figure S5. NOESY spectrum (600 MHz, Chloroform-d) of compound 1



COMMENTS: File name:d\本持党\4-7-3-2-.bka Savitzky-Golay Smooth of sav-golay Window Points=15 Polynomial Orde=3 Derivative=0

Figure S6. CD spectrum of compound 1




Figure S7. HRESIMS spectrum of compound 1





Figure S8. Key HMBC correlations of 1.



**Figure S9.** Key NOESY correlations of **1**(----).






Figure S10. (a) Experimental and calculated <sup>13</sup>C chemical shifts of (2S\*,3S\*,4R\*,5R\*, 6S\*, 7R\*, 8S\*,9R\*,10S\*, 11R\*,13R\*,14R\*)-1. Regression analysis of experimental versus calculated <sup>13</sup>C-NMR chemical shifts of (2S\*,3S\*,4R\*,5R\*,6S\*, 7R\*,8S\*,9R\*, 10S\*, 11R\*, 13R\*,14R\*)-1 at the TMS B3LYP/6-311 + G(2d,p) GIAO level. Linear fitting is shown as a line. (b) Comparison of calculated ECD spectra with the experimental spectrum of 1.








Figure S12. Stereoviews for 2*S*, 3*S*, 4*R*, 5*R*, 6*S*, 7*R*, 8*S*, 9*R*, 10*S*, 11*R*, 13*R*, 14*R* and 2*R*, 3*R*, 4*S*, 5*S*, 6*R*, 7*S*, 8*R*, 9*S*, 10*R*, 11*S*, 13*S*, 14*S* of compound 1. Bold lines denote the electric transition dipole of the chromophores for compound 1.

Position		$1^{\mathrm{a}}$
No.	$\delta_{ m C}$	$\delta_{ m H}(J  ext{ in Hz})$
1a	34.2	1.82 (1H, m)
1b		1.21 (1H, m)
2	33.6	2.23 (1H, m)
3	73.2	4.14 (1H, d, <i>J</i> = 9.0 Hz)
4	90.5	-
5	84.4	6.27 (1H, s)
6	83.3	-
7	79.5	4.29 (1H, d, <i>J</i> = 3.0 Hz)
8	44.4	2.17 (1H, brs)
9	73.4	-
10	49.0	1.94 (1H, m)
11	36.7	1.56 (1H, m)
12a	35.8	1.89 (1H, m)
12b		1.80 (1H, m)
13	75.1	-
14	72.3	4.22 (1H, brs)
15	144.8	-
16	115.1	5.14 (1H, s), 5.13 (1H, s)
17	19.3	1.85 (3H, s)
18	13.9	0.88 (3H, d, <i>J</i> = 6.4 Hz)
19	15.7	0.96 (3H, d, <i>J</i> = 7.2 Hz)
20a	64.8	3.64 (1H, d, <i>J</i> = 11.7 Hz)
20b		3.73 (1H, d, <i>J</i> = 11.7 Hz)
1'	167.6	-
2'	129.3	-
3',7'	130.1	8.04 (2H, d, <i>J</i> = 7.3 Hz)
4',6'	128.8	7.43 (2H, m)
5'	133.7	7.56 (1H, t, J = 7.4 Hz)

 Table S1. <sup>1</sup>H and <sup>13</sup>C-NMR spectral data of compound 1

 $^{\rm al}{\rm H}$  (600 MHz) and  $^{\rm 13}{\rm C}$  (100 MHz) in CDCl3.


lines			
C 1	IC <sub>50</sub> (μM)		
Compound	3B <sup>a</sup>	MCF-7 <sup>a</sup>	
1	>100	>100	
2	$38.55\pm2.76$	$19.92\pm0.33$	
3	$42.24\pm1.24$	$7.31 \pm 0.48$	
4	>100	>100	
5	$8.86\pm0.18$	$17.62\pm0.75$	
5-fluorouracil	$18.42 \pm 1.01$	$39.83\pm 0.56$	

Table S2. Cytotoxic activities of compounds 1-5 against the Hep3B and MCF-7 cell

 $^{a}$ All data were shown as means  $\pm$  SD of three independent experiments.

**Table S3.** Conformations of  $(2S^*, 3S^*, 4R^*, 5R^*, 6S^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 were obtained after the optimization.


14K*)-	<b>1</b> were obtained after the optimization.	
(6S*)1		
no.	conformer	population(%)
(6S*)1-1		0.01
(6S*)1-2		0.78



((C*)17	
(6 <i>S</i> *)1-7	19.42
(6 <i>S*</i> )1-8	0.9
(6 <i>S*</i> )1-9	0.09
(6 <i>S*</i> )1-10	0.19

(6S*)1-11	6.92
(6 <i>S*</i> )1-12	34.5
(6 <i>S*</i> )1-13	0.9
(6S*)1-14	3.72

(6 <i>S*</i> )1-15	
	3.72
(6S*)1-16	19.18
(6 <i>S*</i> )1-17	2.13
(65*)1-18	2.13



**Table S4.** Conformations of  $(2S^*, 3S^*, 4R^*, 5R^*, 6R^*, 7R^*, 8S^*, 9R^*, 10S^*, 11R^*, 13R^*, 14R^*)$ -1 were obtained after the optimization.


= )	<b>j-1</b> were obtained after the optimization.	
(6 <i>R</i> *)1		
no.	conformer	population(%)
(6 <i>R</i> *)1-1		8.67

(6 <i>R</i> *)1-2	69.65
(6 <i>R</i> *)1-3	0.99
(6 <i>R</i> *)1-4	8.67
(6 <i>R</i> *)1-5	0

(6R*)1-6	0.45
(6 <i>R*</i> )1-7	1
(6 <i>R*</i> )1-8	0.17
(6R*)1-9	0.05

(6 <i>R*</i> )1-10	2.89
(6 <i>R*</i> )1-11	2.99
(6 <i>R</i> *)1-12	0.73
(6 <i>R</i> *)1-13	0

(6R*)1-14	0.93
(6 <i>R</i> *)1-15	0
(6 <i>R*</i> )1-16	0
(6R*)1-17	0



**Table S5.** Deviations between the calculated and experimental <sup>13</sup>C NMR chemical shifts for stereoisomers ( $2S^*$ , $3S^*$ , $4R^*$ , $5R^*$ , $6S^*$ , $7R^*$ , $8S^*$ , $9R^*$ , $10S^*$ , $11R^*$ , $13R^*$ , $14R^*$  and  $2S^*$ , $3S^*$ , $4R^*$ , $5R^*$ , $6R^*$ , $7R^*$ , $8S^*$ , $9R^*$ , $10S^*$ , $11R^*$ , $13R^*$ , $14R^*$ ) of **1** 

EXL		6S*			6R*			
	calc.	scal.calc.	Δδ	$ \Delta \delta $	calc.	scal.calc.	Δδ	Δδ
13.9	8.7	12.3	-1.6	1.6	9.1	12.6	-1.3	1.3
15.7	10.9	14.6	-1.1	1.1	11.4	15.0	-0.7	0.7
19.3	13.6	17.5	-1.8	1.8	13.7	17.5	-1.8	1.8
33.6	28.3	33.4	-0.2	0.2	28.3	33.3	-0.3	0.3
34.2	29.0	34.2	0.0	0.0	29.2	34.2	0.0	0.0
35.8	30.2	35.5	-0.3	0.3	29.7	34.7	-1.1	1.1
36.7	31.0	36.3	-0.4	0.4	30.6	35.8	-0.9	0.9
44.4	41.5	47.6	3.2	3.2	42.8	48.9	4.5	4.5
49.0	44.5	50.9	1.9	1.9	43.9	50.1	1.1	1.1
64.8	58.0	65.4	0.6	0.6	56.4	63.6	-1.2	1.2
72.3	60.4	68.0	-4.3	4.3	60.1	67.5	-4.8	4.8
73.2	65.3	73.3	0.1	0.1	64.3	72.1	-1.1	1.1

73.4	66.6	74.7	1.3	1.3	66.7	74.6	1.2	1.2
75.1	68.2	76.4	1.3	1.3	69.9	78.1	3.0	3.0
79.5	73.2	81.8	2.3	2.3	71.4	79.7	0.2	0.2
83.3	75.3	84.1	0.8	0.8	78.0	86.8	3.5	3.5
84.4	76.5	85.3	0.9	0.9	78.7	87.6	3.2	3.2
90.5	84.2	93.7	3.2	3.2	84.5	93.8	3.3	3.3
115.1	101.4	112.2	-2.9	2.9	101.1	111.7	-3.4	3.4
128.8	114.8	126.7	-2.1	2.1	114.9	126.6	-2.2	2.2
128.8	115.1	127.0	-1.8	1.8	115.1	126.8	-2.0	2.0
129.3	116.0	127.9	-1.4	1.4	115.7	127.5	-1.8	1.8
130.1	117.1	129.2	-0.9	0.9	117.2	129.1	-1.0	1.0
130.1	117.9	130.0	-0.1	0.1	117.7	129.6	-0.5	0.5
133.7	120.0	132.3	-1.4	1.4	120.1	132.2	-1.5	1.5
144.8	136.6	150.2	5.4	5.4	137.8	151.3	6.5	6.5
167.6	151.9	166.8	-0.8	0.8	151.8	166.4	-1.2	1.2
			AveDev	1.6			AveDev	2.0
			MaxDev	5.4			MaxDev	6.5
			R <sup>2</sup>	0.9978			R <sup>2</sup>	0.9966